Mankind Pharma Receives Order from CGST, Haryana; to Appeal
Mankind Pharma received an order from CGST, Haryana, with a penalty of ₹83.01 lakh for FY 2021-22. The company will appeal, citing the order as arbitrary and without material financial impact.
The company explicitly states that there is no material impact on financials, operations, or other activities. Although a penalty is involved, the company is contesting it.
The announcement conveys factual information about receiving an order and the company's plan to appeal. While the order itself could be seen negatively, the company states it believes it's unjustified and won't have a material impact.
* Mankind Pharma Limited received an order from the Commissioner Goods and Service Tax, Haryana on November 14, 2025. * The order was issued by Additional Commissioner, CGST, Gurugram, Haryana, under Section 73 of the Central Goods and Services Tax Act, 2017. * The order pertains to FY 2021-22 and levies a penalty of ₹83,00,790. * The GST Authority passed the order due to the alleged disallowance of ITC under Section 16(4) of the CGST Act. * The company considers the order arbitrary and unjustified and will file an appeal. * Mankind Pharma believes there will be no material impact on the company's financials, operations, or other activities.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.